VerImmune's scientific advisors publishes independent supportive data on Anti-tumor Immune Redirection (AIR) in PNAS

VerImmune extends it’s deepest congratulations to our collaborators & advisors at the NCI (National Cancer Institute) for their new peer-review scientific publication.

The publication entitled Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors was published in the prestigious Proceedings of the National Academy of Sciences (PNAS) journal.

The preclinical studies published were conducted independently from VerImmune Inc and demonstrated that reactivated viral immunity could be redirected to target non-viral tumors. The authors utilized specifically a murine cytomegalovirus (CMV) model and showed that reactivating CMV T-cells resulted in a therapeutic effect in several murine tumor models including immunologically cold tumor models.

The publication was also featured in ACIR (Accelerating Cancer Immunotherapy Research)’s weekly digest that covers weekly synopsis of the most exciting and key advances in the field of cancer immunotherapy.

Link to Scientific Publication: https://www.pnas.org/doi/epdf/10.1073/pnas.2116738119

Link to ACIR’s weekly digest: https://acir.org/weekly-digests/2022/july/reactivating-viral-immunity-to-treat-non-viral-tumors